""

about | Maps & Directions | contact | admissions | faculty | alumni & development | library | Tech Support Center | dean's office | Policies & Procedures

FAculty directory

Dr. Ronald TallaridaBack to alphabetical index

 

Ronald Tallarida, PhD

 

Professor, Pharmacology

Telephone:  215-707- 3243

Fax:  215-707-6661

Email: ronald.tallarida@temple.edu

 

Department of Pharmacology

Center for Substance Abuse Research

 

 

Educational Background:

 

B.S. Drexel University Philadelphia, PA  1959

 

M.S. Drexel University Philadelphia, PA 1963

 

Ph.D. Temple University Philadelphia, PA 1967

Return to top

 

 

Research Interests:

 

Dose-response curve

Research interests involve combination studies of opioids as well as othe drugs of abuse. In addition, we are interested in synergistic interactions between vasoconstructors. The work involves statisical analysis, experimental design and modeling. Interactions between opioids are measured in behavorial mouse models.

 

Return to top

 

 

PUBMED PUBLICATIONS :


Recent Medically Related Publications, Obtained from PubMed (Click on PubMed ID to view abstract)

25485642. Neelakantan H, Tallarida RJ, Reichenbach ZW, Tuma RF, Ward SJ, Walker EA, Distinct interactions of cannabidiol and morphine in three nociceptive behavioral models in mice. Behav Pharmacol :()2014 Dec 5

25212751. Tallarida CS, Bires K, Avershal J, Tallarida RJ, Seo S, Rawls SM, Ethanol and cocaine: environmental place conditioning, stereotypy, and synergism in planarians. Alcohol 48:6(579-86)2014 Sep

24574066. Cowan A, Raffa RB, Tallarida CS, Tallarida RJ, Christoph T, Schröder W, Tzschentke TM, Lack of synergistic interaction between the two mechanisms of action of tapentadol in gastrointestinal transit. Eur J Pain 18:8(1148-56)2014 Sep

24440755. Tallarida CS, Egan E, Alejo GD, Raffa R, Tallarida RJ, Rawls SM, Levamisole and cocaine synergism: a prevalent adulterant enhances cocaine's action in vivo. Neuropharmacology 79:(590-5)2014 Apr

24051022. Christoph T, Schröder W, Tallarida RJ, De Vry J, Tzschentke TM, Spinal-supraspinal and intrinsic µ-opioid receptor agonist-norepinephrine reuptake inhibitor (MOR-NRI) synergy of tapentadol in diabetic heat hyperalgesia in mice. J Pharmacol Exp Ther 347:3(794-801)2013 Dec

23550787. Tallarida RJ, Midic U, Lamarre NS, Obradovic Z, A search for interaction among combinations of drugs of abuse and the use of isobolographic analysis. J Clin Pharm Ther 38:3(190-5)2013 Jun

23270987. Lamarre NS, Raffa RB, Tallarida RJ, Cocaine synergism with a agonists in rat aorta: computational analysis reveals an action beyond reuptake inhibition. Drug Alcohol Depend 129:3(226-31)2013 May 1

22737266. Tallarida RJ, Quantitative methods for assessing drug synergism. Genes Cancer 2:11(1003-8)2011 Nov

22511201. Tallarida RJ, Revisiting the isobole and related quantitative methods for assessing drug synergism. J Pharmacol Exp Ther 342:1(2-8)2012 Jul

22420908. Raffa RB, Tallarida RJ, Taylor R Jr, Pergolizzi JV Jr, Fixed-dose combinations for emerging treatment of pain. Expert Opin Pharmacother 13:9(1261-70)2012 Jun

22300981. Ramoz L, Lodi S, Bhatt P, Reitz AB, Tallarida C, Tallarida RJ, Raffa RB, Rawls SM, Mephedrone ("bath salt") pharmacology: insights from invertebrates. Neuroscience 208:(79-84)2012 Apr 19

22037914. Tallarida RJ, Lamarre N, Raffa RB, 'Null method' determination of drug biophase concentration. Pharm Res 29:3(637-42)2012 Mar

21910983. Lamarre NS, Parry T, Tallarida RJ, On the quantitation of an agonist with dual but opposing components of action: application to vascular endothelial relaxation. Eur J Pharmacol 670:1(204-7)2011 Nov 16

21466813. Iwuchukwu OF, Tallarida RJ, Nagar S, Resveratrol in combination with other dietary polyphenols concomitantly enhances antiproliferation and UGT1A1 induction in Caco-2 cells. Life Sci 88:23-24(1047-54)2011 Jun 6

20831527. Raffa RB, Tallarida RJ, Effects on the visual system might contribute to some of the cognitive deficits of cancer chemotherapy-induced 'chemo-fog'. J Clin Pharm Ther 35:3(249-55)2010 Jun

20738019. Raffa RB, Tallarida RJ, Future directions. Adv Exp Med Biol 678:(165-7)2010

20738015. Tallarida RJ, Combination analysis. Adv Exp Med Biol 678:(133-7)2010

20737998. Raffa RB, Tallarida RJ, Chemo fog: cancer chemotherapy-related cognitive impairment. Preface. Adv Exp Med Biol 678:(vii-viii)2010

20571607. Raffa RB, Pergolizzi JV, Segarnick DJ, Tallarida RJ, Oxycodone combinations for pain relief. Drugs Today (Barc) 46:6(379-98)2010 Jun

20546783. Tallarida RJ, Raffa RB, The application of drug dose equivalence in the quantitative analysis of receptor occupation and drug combinations. Pharmacol Ther 127:2(165-74)2010 Aug

20347018. Miller JS, Tallarida RJ, Unterwald EM, Inhibition of GSK3 attenuates dopamine D1 receptor agonist-induced hyperactivity in mice. Brain Res Bull 82:3-4(184-7)2010 May 31

20338825. Raffa RB, Pergolizzi JV Jr, Tallarida RJ, The determination and application of fixed-dose analgesic combinations for treating multimodal pain. J Pain 11:8(701-9)2010 Aug

20133950. Vegesna AK, Braverman AS, Miller LS, Tallarida RJ, Tiwana MI, Khayyam U, Ruggieri MR Sr, Comparison of human and porcine gastric clasp and sling fiber contraction by M2 and M3 muscarinic receptors. Am J Physiol Gastrointest Liver Physiol 298:4(G530-4)2010 Apr

20061095. Tallarida RJ, Cowan A, Raffa RB, On deriving the dose-effect relation of an unknown second component: an example using buprenorphine preclinical data. Drug Alcohol Depend 109:1-3(126-9)2010 Jun 1

19328817. Miller JS, Tallarida RJ, Unterwald EM, Cocaine-induced hyperactivity and sensitization are dependent on GSK3. Neuropharmacology 56:8(1116-23)2009 Jun

19126780. Braverman AS, Miller LS, Vegesna AK, Tiwana MI, Tallarida RJ, Ruggieri MR Sr, Quantitation of the contractile response mediated by two receptors: M2 and M3 muscarinic receptor-mediated contractions of human gastroesophageal smooth muscle. J Pharmacol Exp Ther 329:1(218-24)2009 Apr

18371948. Lamarre NS, Tallarida RJ, A quantitative study to assess synergistic interactions between urotensin II and angiotensin II. Eur J Pharmacol 586:1-3(350-1)2008 May 31

18339971. Braverman AS, Tallarida RJ, Ruggieri MR Sr, The use of occupation isoboles for analysis of a response mediated by two receptors: M2 and M3 muscarinic receptor subtype-induced mouse stomach contractions. J Pharmacol Exp Ther 325:3(954-60)2008 Jun

18256173. Ward SJ, Lefever TW, Jackson C, Tallarida RJ, Walker EA, Effects of a Cannabinoid1 receptor antagonist and Serotonin2C receptor agonist alone and in combination on motivation for palatable food: a dose-addition analysis study in mice. J Pharmacol Exp Ther 325:2(567-76)2008 May

17592517. Rawls SM, Tallarida R, Robinson W, Amin M, The beta-lactam antibiotic, ceftriaxone, attenuates morphine-evoked hyperthermia in rats. Br J Pharmacol 151:7(1095-102)2007 Aug

17194800. Benamar K, Yondorf M, Meissler JJ, Geller EB, Tallarida RJ, Eisenstein TK, Adler MW, A novel role of cannabinoids: implication in the fever induced by bacterial lipopolysaccharide. J Pharmacol Exp Ther 320:3(1127-33)2007 Mar

17141755. Raffa RB, Stagliano GW, Tallarida RJ, Nonlinear isobologram and superadditive withdrawal from cocaine: cannabinoid combinations in planarians. Eur J Pharmacol 556:1-3(89-90)2007 Feb 5

17109846. Rawls SM, Tallarida RJ, Zisk J, Agmatine and a cannabinoid agonist, WIN 55212-2, interact to produce a hypothermic synergy. Eur J Pharmacol 553:1-3(89-98)2006 Dec 28

17079019. Tallarida RJ, Interactions between drugs and occupied receptors. Pharmacol Ther 113:1(197-209)2007 Jan

17045985. Raffa RB, Tallarida RJ, Modified 'Joyce model' of opioid dependence/withdrawal. Eur J Pharmacol 551:1-3(54-7)2006 Dec 3

17018247. Ding Z, Cowan A, Tallarida R, Rawls SM, Capsaicin and nitric oxide synthase inhibitor interact to evoke a hypothermic synergy. Neurosci Lett 409:1(41-6)2006 Nov 27

16914122. Raffa RB, Stagliano GW, Tallarida RJ, Subadditive withdrawal from cocaine/kappa-opioid agonist combinations in Planaria. Brain Res 1114:1(31-5)2006 Oct 9

16737694. Raffa RB, Baron DA, Tallarida RJ, Schild (apparent pA2) analysis of a kappa-opioid antagonist in Planaria. Eur J Pharmacol 540:1-3(200-1)2006 Jul 1

16670349. Tallarida RJ, An overview of drug combination analysis with isobolograms. J Pharmacol Exp Ther 319:1(1-7)2006 Oct

16257420. Chen X, McClatchy DB, Geller EB, Tallarida RJ, Adler MW, The dynamic relationship between mu and kappa opioid receptors in body temperature regulation. Life Sci 78:4(329-33)2005 Dec 12

16137704. Rawls SM, Jacobs K, Tallarida RJ, Baclofen and NOS inhibitors interact to evoke synergistic hypothermia in rats. Life Sci 78:7(669-72)2006 Jan 11

15640611. Schulingkamp RJ, Aloyo V, Tallarida RJ, Raffa RB, Changes in aorta alpha1-adrenoceptor number and affinity during one year of streptozotocin-induced diabetes in rats. Pharmacology 74:1(23-30)2005 Apr

15476754. Rawls SM, Baron DA, Gomez T, Jacobs K, Tallarida RJ, Pronounced hypothermic synergy between systemic baclofen and NOS inhibitor. Eur J Pharmacol 502:3(271-2)2004 Oct 19

15175417. Grabovsky Y, Tallarida RJ, Isobolographic analysis for combinations of a full and partial agonist: curved isoboles. J Pharmacol Exp Ther 310:3(981-6)2004 Sep

15159137. Rawls SM, Tallarida RJ, Kon DA, Geller EB, Adler MW, GABAA receptors modulate cannabinoid-evoked hypothermia. Pharmacol Biochem Behav 78:1(83-91)2004 May

14751409. Inan S, Tallarida RJ, Morphine potentiates dextromethorphan-induced vasodilation in rat superior mesenteric artery. Eur J Pharmacol 486:1(61-5)2004 Feb 13

14610231. Rawls SM, Tallarida RJ, Gray AM, Geller EB, Adler MW, L-NAME (N omega-nitro-L-arginine methyl ester), a nitric-oxide synthase inhibitor, and WIN 55212-2 [4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1ij]quinolin-6-one], a cannabinoid agonist, interact to evoke synergistic hypothermia. J Pharmacol Exp Ther 308:2(780-6)2004 Feb

14521480. Raffa RB, Clark-Vetri R, Tallarida RJ, Wertheimer AI, Combination strategies for pain management. Expert Opin Pharmacother 4:10(1697-708)2003 Oct

12966152. Tallarida RJ, Cowan A, Raffa RB, Antinociceptive synergy, additivity, and subadditivity with combinations of oral glucosamine plus nonopioid analgesics in mice. J Pharmacol Exp Ther 307:2(699-704)2003 Nov

12388658. Field MJ, Gonzalez MI, Tallarida RJ, Singh L, Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain. J Pharmacol Exp Ther 303:2(730-5)2002 Nov

Return to top